Omnicell To Present At The 2014 Stephens Inc. Fall Investment Conference

MOUNTAIN VIEW, Calif., Nov. 5, 2014 /PRNewswire/ -- Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication and supply management solutions and analytics software for healthcare facilities, today announced it will present at the 2014 Stephens Inc. Fall Investment Conference at the New York Palace Hotel, New York, NY. 

Omnicell, Inc. logo

Omnicell Speakers: Rob Seim, Executive Vice President & CFO

Date:Wednesday, November 12, 2014
Time: 2:00 p.m. ET
Location: New York Palace Hotel, New York, NY
Availability: The audio-webcast of the live presentation may be accessed by visiting:
http://ir.omnicell.com/events.cfm

Following the conference, a replay of the audio-webcast will be archived for 30 days on the Omnicell website.

About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been creating new efficiencies to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire healthcare continuum from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.

More than 3,000 customers worldwide have utilized Omnicell Automation and Analytics solutions to increase operational efficiency, reduce errors, deliver actionable intelligence and improve patient safety. Omnicell Medication Adherence solutions, including its MTS Medication Technologies brand, provide innovative medication adherence packaging solutions to help reduce costly hospital readmissions. In addition, these solutions enable approximately 6,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.

OMCL-E

Logo - http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a

SOURCE Omnicell, Inc.

Help employers find you! Check out all the jobs and post your resume.

Back to news